Developer docs
API playgroundTry for free, no card

Search company profiles

Misonix

Full company profile

uuid0005cod

Namestring
Misonix
Legal namestring
Misonix LLC
Websiteurl
misonix.com
Company typeenum
Private
Founded yearint
1955
Descriptiontext

Misonix is a medical device company specializing in the design, development, manufacture, and marketing of ultrasonic surgical instruments used for precise bone cutting and soft tissue ablation. Founded in 1955 and headquartered in Farmingdale, United States, Misonix operates as a publicly traded entity (nasdaq:MSON) under the legal name Misonix LLC, with a workforce of 51–100 employees. The core technology converts ultrasonic energy into controlled cutting and ablation, intended to deliver precise bone cuts while minimizing thermal damage to surrounding tissue — a functional benefit relevant to spine, neurosurgical, and orthopedic procedures where conventional high-speed or powered instruments carry collateral-injury risk.

The company's product portfolio centers on three registered-trademark platforms: BoneScalpel (with Legacy and Access variants for varied surgical approaches), SonaStar (Elite and Legacy variants for soft tissue ablation and bone cutting), and SonicOne O.R., an integrated operating-room platform that combines bone cutting and soft tissue ablation capabilities. These devices are documented as FDA 510(k)-cleared, with regulatory clearance letters maintained as part of Bioventus Surgical's resource library. Sub-brands and product variants are distributed and sold through Bioventus Surgical's orthobiologics portfolio, suggesting a channel partnership or post-acquisition distribution relationship between Misonix LLC and Bioventus, though the precise ownership structure is not disclosed in the source data.

Misonix's business model combines capital-equipment sales (the ultrasonic consoles) with recurring consumable revenue (single-use tips and accessories) sold into hospitals and surgical specialist practices. Customers are primarily orthopedic surgeons, neurosurgeons, and other surgical specialists performing procedures that require precise bone cutting with controlled thermal margins. Pricing is not publicly disclosed. The company has pursued inorganic growth — most notably acquiring Solsys Medical in May 2019 for approximately $97 million, and earlier acquiring Fibra Sonics in 2001 — while also raising growth equity from healthcare-focused investors including 1315 Capital and SV Health Investors ($25 million in November 2017, followed by a $30 million round in January 2020).

Short descriptiontext

Misonix designs, manufactures, and markets ultrasonic surgical devices (BoneScalpel, SonaStar, SonicOne O.R.) for precise bone cutting and soft tissue ablation. The company serves orthopedic surgeons, neurosurgeons, and other surgical specialists in hospital operating rooms, distributing products through Bioventus Surgical's orthobiologics channel.

Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersFarmingdale, United States
HQ citystring
Farmingdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
ultrasonic surgical devices, bone cutting instruments, tissue ablation systems, surgical ultrasonic platforms, operating room equipment
Industry1 code
1Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
CodeHLAHADAAPrimaryYes
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Surgical Ultrasonic Devices
Social media profiles1 record
Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1BoneScalpel
Description

Registered trademark of Misonix LLC, a surgical ultrasonic device product line

bioventussurgical.com
+2 more records
Core offering1 text field

Misonix designs, develops, manufactures, and markets ultrasonic surgical devices used for precise bone cutting and soft tissue ablation in surgical procedures. Its core product portfolio includes the BoneScalpel, SonaStar, and SonicOne O.R. systems, which are sold and distributed through Bioventus Surgical's orthobiologics portfolio to surgical specialists and hospitals.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Misonix offers a portfolio of ultrasonic surgical systems primarily consisting of the BoneScalpel, SonaStar, and SonicOne product lines. These devices utilize ultrasonic technology for precise bone cutting and soft tissue ablation in surgical procedures. The product portfolio includes multiple variants (Legacy, Elite, Access) that serve different surgical approaches and facility needs. BoneScalpel variants focus on bone cutting applications, SonaStar variants emphasize soft tissue ablation capabilities, while SonicOne O.R. represents an integrated operating room platform combining both capabilities.

Product and service3 records
1BoneScalpel
CategoryUltrasonic Bone Cutting Systems
Description

Ultrasonic surgical device designed for precise bone cutting with minimal thermal damage to surrounding tissues. Available in multiple variants including Legacy and Access versions. Used by orthopedic surgeons, neurosurgeons, and other surgical specialists performing procedures requiring precise bone cutting.

2SonaStar
CategoryUltrasonic Soft Tissue Ablation Systems
Description

Ultrasonic surgical system for soft tissue ablation and bone cutting, offering precision in surgical procedures. Available in Elite and Legacy variants. Used by surgical specialists requiring both ablation and cutting capabilities.

3SonicOne O.R.
CategoryIntegrated Operating Room Ultrasonic Platforms
Description

Operating room ultrasonic surgical system combining bone cutting and soft tissue ablation capabilities in a single integrated platform. Used by hospitals and surgical centers for procedures requiring a versatile ultrasonic surgical solution.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers3 records
1Olympus
TypeBroad incumbent
2Ethicon (Johnson & Johnson)
TypeBroad incumbent
Description

Ethicon's Harmonic ultrasonic devices compete with Misonix's soft-tissue ablation products (SonaStar) in general and specialty surgery. Ethicon brings global distribution, bundled energy-device contracts, and far larger R&D resources, making it a key incumbent competitor.

3Stryker
TypeBroad incumbent
Description

Stryker's SONOPET ultrasonic surgical aspirator competes directly with Misonix's SonaStar and BoneScalpel in spine and neurosurgery. Stryker's vastly larger sales force, capital, and broader surgical portfolio make it the most relevant scaled competitor in the same product category.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Misonix

Surgical Ultrasonic Devicesmisonix.com

Misonix designs, manufactures, and markets ultrasonic surgical devices (BoneScalpel, SonaStar, SonicOne O.R.) for precise bone cutting and soft tissue ablation. The company serves orthopedic surgeons, neurosurgeons, and other surgical specialists in hospital operating rooms, distributing products through Bioventus Surgical's orthobiologics channel.

What Misonix does

Misonix is a medical device company specializing in the design, development, manufacture, and marketing of ultrasonic surgical instruments used for precise bone cutting and soft tissue ablation. Founded in 1955 and headquartered in Farmingdale, United States, Misonix operates as a publicly traded entity (nasdaq:MSON) under the legal name Misonix LLC, with a workforce of 51–100 employees. The core technology converts ultrasonic energy into controlled cutting and ablation, intended to deliver precise bone cuts while minimizing thermal damage to surrounding tissue — a functional benefit relevant to spine, neurosurgical, and orthopedic procedures where conventional high-speed or powered instruments carry collateral-injury risk.

The company's product portfolio centers on three registered-trademark platforms: BoneScalpel (with Legacy and Access variants for varied surgical approaches), SonaStar (Elite and Legacy variants for soft tissue ablation and bone cutting), and SonicOne O.R., an integrated operating-room platform that combines bone cutting and soft tissue ablation capabilities. These devices are documented as FDA 510(k)-cleared, with regulatory clearance letters maintained as part of Bioventus Surgical's resource library. Sub-brands and product variants are distributed and sold through Bioventus Surgical's orthobiologics portfolio, suggesting a channel partnership or post-acquisition distribution relationship between Misonix LLC and Bioventus, though the precise ownership structure is not disclosed in the source data.

Misonix's business model combines capital-equipment sales (the ultrasonic consoles) with recurring consumable revenue (single-use tips and accessories) sold into hospitals and surgical specialist practices. Customers are primarily orthopedic surgeons, neurosurgeons, and other surgical specialists performing procedures that require precise bone cutting with controlled thermal margins. Pricing is not publicly disclosed. The company has pursued inorganic growth — most notably acquiring Solsys Medical in May 2019 for approximately $97 million, and earlier acquiring Fibra Sonics in 2001 — while also raising growth equity from healthcare-focused investors including 1315 Capital and SV Health Investors ($25 million in November 2017, followed by a $30 million round in January 2020).

Misonix firmographics

Firmographics
Name
Misonix
Legal name
Misonix LLC
Website
https://misonix.com
Company type
Private
Founded year
1955
Headcount range
51–100 employees
Short description
Misonix designs, manufactures, and markets ultrasonic surgical devices (BoneScalpel, SonaStar, SonicOne O.R.) for precise bone cutting and soft tissue ablation. The company serves orthopedic surgeons, neurosurgeons, and other surgical specialists in hospital operating rooms, distributing products through Bioventus Surgical's orthobiologics channel.
Ownership category
akta.pro rank

Misonix industry classification

Industry
Product category
Surgical Ultrasonic Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro primary industry
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)

Keywords

  • Ultrasonic surgical devices
  • Bone cutting instruments
  • Tissue ablation systems
  • Surgical ultrasonic platforms
  • Operating room equipment

Where Misonix is headquartered

Location

Headquarters

HQ city
Farmingdale
HQ country
United States
HQ region
North America

Markets served

Misonix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Misonix product offering

Product offering

Core offering

Misonix designs, develops, manufactures, and markets ultrasonic surgical devices used for precise bone cutting and soft tissue ablation in surgical procedures. Its core product portfolio includes the BoneScalpel, SonaStar, and SonicOne O.R. systems, which are sold and distributed through Bioventus Surgical's orthobiologics portfolio to surgical specialists and hospitals.

Product overview

Misonix offers a portfolio of ultrasonic surgical systems primarily consisting of the BoneScalpel, SonaStar, and SonicOne product lines. These devices utilize ultrasonic technology for precise bone cutting and soft tissue ablation in surgical procedures. The product portfolio includes multiple variants (Legacy, Elite, Access) that serve different surgical approaches and facility needs. BoneScalpel variants focus on bone cutting applications, SonaStar variants emphasize soft tissue ablation capabilities, while SonicOne O.R. represents an integrated operating room platform combining both capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • BoneScalpel: Registered trademark of Misonix LLC, a surgical ultrasonic device product line
  • SonaStar
  • SonicOne O.R.

Products and services

  • BoneScalpel Ultrasonic surgical device designed for precise bone cutting with minimal thermal damage to surrounding tissues. Available in multiple variants including Legacy and Access versions. Used by orthopedic surgeons, neurosurgeons, and other surgical specialists performing procedures requiring precise bone cutting.
  • SonaStar Ultrasonic surgical system for soft tissue ablation and bone cutting, offering precision in surgical procedures. Available in Elite and Legacy variants. Used by surgical specialists requiring both ablation and cutting capabilities.
  • SonicOne O.R. Operating room ultrasonic surgical system combining bone cutting and soft tissue ablation capabilities in a single integrated platform. Used by hospitals and surgical centers for procedures requiring a versatile ultrasonic surgical solution.

Companies that use Misonix

Customer profile

Segments1 record

Ideal customer profiles1 record

Misonix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Misonix partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights4 records

Misonix competitors and assessment

Company assessment

Broad incumbents

  • Olympus:
  • Ethicon (Johnson & Johnson): Ethicon's Harmonic ultrasonic devices compete with Misonix's soft-tissue ablation products (SonaStar) in general and specialty surgery. Ethicon brings global distribution, bundled energy-device contracts, and far larger R&D resources, making it a key incumbent competitor.
  • Stryker: Stryker's SONOPET ultrasonic surgical aspirator competes directly with Misonix's SonaStar and BoneScalpel in spine and neurosurgery. Stryker's vastly larger sales force, capital, and broader surgical portfolio make it the most relevant scaled competitor in the same product category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Misonix social profiles

Digital presence

Misonix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Misonix leadership team

Management profile

Number of profiles

Profiles2 records

Misonix funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Misonix M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Misonix

What does Misonix do?

Misonix designs, develops, manufactures, and markets ultrasonic surgical devices used for precise bone cutting and soft tissue ablation in surgical procedures. Its core product portfolio includes the BoneScalpel, SonaStar, and SonicOne O.R. systems, which are sold and distributed through Bioventus Surgical's orthobiologics portfolio to surgical specialists and hospitals.

When was Misonix founded?

Misonix was founded in 1955. It employs 51 to 100 people.

Where is Misonix based?

Misonix is headquartered in Farmingdale, United States, in the North America region.

Who are Misonix's main competitors?

Broad incumbents on record are Olympus, Ethicon (Johnson & Johnson) and Stryker.

Does Misonix have an API?

No public API is recorded for Misonix.

What industry is Misonix in?

Misonix's product category is Surgical Ultrasonic Devices. Its primary akta.pro industry code is HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSHAREHOLDER ALERT: WeissLaw LLP Reminds HOMB, SC, MSON, and SBKK Shareholders About Its Ongoing InvestigationsWeissLaw LLP issued a shareholder alert notifying investors about its ongoing investigations into possible breaches of fiduciary duty by the boards of four companies in connection with pending merger transactions. The investigations cover Home BancShares' proposed acquisition of Happy Bancshares, Santander Consumer USA's proposed acquisition by Santander Holdings USA, Misonix's proposed acquisition by Bioventus, and Suncrest Bank's proposed acquisition by CVB Financial Corp. Shareholders of these companies are being encouraged to contact WeissLaw to discuss their rights or the investigations.PR NewswireSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Misonix, Inc. - MSONMonteverde & Associates PC, a securities litigation law firm, has announced an investigation into Misonix, Inc. regarding its proposed acquisition by Bioventus, Inc., under which Misonix shareholders will receive either $28.25 in cash or 1.6839 shares of Bioventus per share. The investigation focuses on whether Misonix and its Board of Directors violated securities laws and/or breached fiduciary duties by failing to conduct a fair process and whether the transaction is properly valued. The law firm is offering free information to shareholders who wish to protect their investments.BenzingaBioventus Scoops Up Misonix In $518M Stock & Cash Deal; Raises FY21 Sales Outlook - Bioventus (NASDAQ:BVSBioventus Inc has agreed to acquire Misonix Inc for $518 million in a cash-and-stock transaction, representing a 17% premium to Misonix's closing price. The deal, expected to close in Q4 2021, is projected to add approximately $80 million to calendar year 2021 revenue and generate $20 million in annual pre-tax cost synergies by the end of the second full year post-closing. Bioventus also raised its FY21 sales guidance to $405-$415 million, up 26%-29% year-over-year, citing the acquisition as accretive to adjusted EBITDA.GlobeNewswireBioventus and Misonix Announce Definitive Agreement forBioventus agreed to acquire Misonix in a cash-and-stock deal valued at approximately $518 million, with Misonix stockholders receiving either 1.6839 Bioventus shares or $28.00 cash per share. The transaction is expected to close in the fourth quarter of 2021 and is subject to regulatory and stockholder approvals.YahooBioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire MisonixBioventus agreed to acquire Misonix in a cash-and-stock deal valued at approximately $518 million, with Misonix stockholders receiving either 1.6839 Bioventus shares or $28.00 cash per share. The transaction is expected to close in the fourth quarter of 2021 and is subject to regulatory and stockholder approvals.GlobeNewswireMisonix Announces Public Offering of Common StockMisonix, Inc. commenced an underwritten public offering of its common stock, with Canaccord Genuity as book-running manager and BTIG and Craig-Hallum as lead managers. The company will use net proceeds for general corporate purposes, including sales and marketing and potential acquisitions. The offering is subject to SEC registration and forward-looking statements.PR NewswireCryoLife and Misonix Enter Into Distribution Agreement for NeoPatchCryoLife and Misonix have entered into a distribution agreement granting Misonix exclusive U.S. commercialization rights for CryoLife's NeoPatch product, a chorioamniotic allograft used in advanced wound care and other surgical applications. The partnership involves a three-year term with minimum purchase obligations, with pilot supplies commencing in the first quarter of 2020 and a full commercial launch expected in the second quarter.GlobeNewswireMisonix, Inc. Completes Acquisition of Regenerative Medical Company Solsys MedicalMisonix completed its acquisition of Solsys Medical in an all-stock deal valued at approximately $109 million. Solsys generated $24 million in revenue in 2018 and is expected to grow over 25% in 2019. The combined company projects product revenue growth exceeding 20% and gross margins of about 70% for fiscal 2020.GlobeNewswireSEC Investigation of Misonix, Inc. Ends With No ActionThe SEC concluded its investigation of Misonix, Inc. and will not recommend enforcement action. The company had previously disclosed a voluntary investigation into its Chinese distributor's practices and internal controls. Misonix remains focused on its strategic growth plan.GlobeNewswireMisonix, Inc. Enters Into Definitive Agreement to Acquire Regenerative Medical Company Solsys Medical for Approximately $97 MillionMisonix entered a definitive agreement to acquire Solsys Medical in an all-stock deal valued at approximately $97 million, issuing about 5.7 million new shares. The combined entity is expected to generate over $80 million in annual revenue for fiscal 2020, with Solsys' TheraSkin product applied to over 100,000 wounds.